PDCD1 and obesity disorder: Finally, while several studies in the context of cancer immunotherapy with PD-1/PD-L1 immune checkpoint inhibitors have demonstrated the favorable impact of obesity, other authors have highlighted that BMI itself may not always represent a most valid surrogate for body composition [25].